Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04893434 · ClinicalTrials.gov registry record · Phase 1
Novel Imaging Technique to Assess Gynecologic Cancer
A Phase 1 study of Gynecologic Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT04893434 is a Phase 1 study of Gynecologic Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants, below the 764-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04893434, a Phase 1 study of Gynecologic Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will test a new type of DCE (dynamic contrast-enhanced) MRI (magnetic resonance imaging) to see whether, compared with traditional MRI, it produces better images that provide more information about tumors, which may help doctors make better decisions about treating women who have gynecologic cancer. MRI is commonly used to detect and evaluate many types of cancer, but its slow processing speed and the risk that images will be blurred if the patient moves inside the scanner can limit its use in clinical practice. DCE MRI is a new imaging technique that uses additional computer processing to collect information continuously during scanning, which produces more detailed images faster than traditional MRI, which reduces the risk of movement-related blurring and provides important information about tumor activity. The DCE MRI scan in this study will be done in a standard MRI scanner, using a contrast agent (gadobutrol; Gadavist®) that has been approved by the FDA.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MRI
- DRUG Gadobutrol
Study Locations (3)
New York
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-05-13 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04893434
The ClinicalTrials.gov registry entry for NCT04893434 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 764-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gynecologic Cancer appearing as the primary indexed condition, and to 2 interventions - of which MRI is the first listed.
NCT04893434 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04893434 about?
NCT04893434 is a clinical study titled "Novel Imaging Technique to Assess Gynecologic Cancer". This study will test a new type of DCE (dynamic contrast-enhanced) MRI (magnetic resonance imaging) to see whether, compared with traditional MRI, it produces better images that provide more information about tumors, which may help doctors make better decisions about treating women who have gynecolo...
What is the current status of trial NCT04893434?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-05-13. Estimated completion is 2027-05.
What conditions does trial NCT04893434 study?
This clinical trial studies the following conditions: Gynecologic Cancer.
What interventions are being tested in trial NCT04893434?
The interventions under investigation include: MRI (DIAGNOSTIC_TEST), Gadobutrol (DRUG).
Who is sponsoring clinical trial NCT04893434?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04893434 being conducted?
This trial has 3 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gynecologic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
RECRUITING · Phase 1
-
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
RECRUITING · Phase 1
-
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.